Press Releases (-) Any 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2022 May 19, 2022 argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases May 10, 2022 argenx announces results of Annual General Meeting of Shareholders May 5, 2022 argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia May 5, 2022 argenx Reports First Quarter 2022 Financial Results and Provides Business Update May 4, 2022 argenx to Present at BofA Securities 2022 Healthcare Conference April 28, 2022 argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022 April 5, 2022 argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting April 1, 2022 argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting March 29, 2022 argenx announces full exercise of underwriters’ option to purchase additional ADSs March 29, 2022 argenx announces Annual General Meeting of Shareholders on May 10, 2022 March 28, 2022 argenx announces closing of global offering March 23, 2022 argenx raises $700 million in gross proceeds in a global offering Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
